Sign in

Private company

TiGenix

TiGenix is a European cell therapy company with a proprietary validated allogeneic expanded adipose-derived stem cell (eASC) platform technology for the treatment of autoimmune and inflammatory diseases, and a commercialized product. Its corporate headquarters are in Leuven, Belgium, and it has operations in Madrid, Spain. TiGenix was founded in 2000 by Prof.3 Wikipedia text CC BY-SA 4.0

Last updated Oct 21, 2026.

Overview

2000Founded1
  • Industrybiotechnology1
  • HeadquartersMadrid1
  • Websitewww.tigenix.com
  • Legal formNaamloze vennootschap4
  • LEI549300U4XEIPPXHC2L054
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressBUS 2, 3001 Leuven, Belgium4
  • Registered withFederal Public Service Economy (Ministry of Economy), 0471.340.1234

See how the biggest companies compare on our leaderboards

TiGenix is a European cell therapy company with a proprietary validated allogeneic expanded adipose-derived stem cell (eASC) platform technology for the treatment of autoimmune and inflammatory diseases, and a commercialized product. Its corporate headquarters are in Leuven, Belgium, and it has operations in Madrid, Spain. TiGenix was founded in 2000 by Prof. Dr. Frank P. Luyten and Gil Beyen as a spin-off from the Katholieke Universiteit Leuven and the Ghent University.3

What it owns

What TiGenix reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net4.5M EUR6 Dec 31, 20171.6M EUR6 Dec 31, 2016+171.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents34.1M EUR6 Dec 31, 201778.0M EUR6 Dec 31, 2016−56.3%

Inventory

ItemLatestA year beforeChange
Inventory, total1.4M EUR6 Dec 31, 2017244.0K EUR6 Dec 31, 2016+479.1%
Raw materials1.4M EUR6 Dec 31, 2017244.0K EUR6 Dec 31, 2016+479.1%

The story

TiGenix has completed and received positive data in, a single pivotal Phase III trial in Europe of its most advanced product candidate Cx601, a potential first-in-class injectable allogeneic stem cell therapy indicated for the treatment of complex perianal fistulas in patients with Crohn's disease. On 28 July 2016 The Lancet published the results of their phase 3 ADMIRE-CD Trial.

Acquisition by Takeda

In early January 2018, Takeda Pharmaceutical Company announced it would acquire TiGenix for up to €520 million ($632 million).

From Wikipedia’s article on TiGenix, shared under CC BY-SA 4.0.5

Timeline

  1. 2000Founded Founded1

SEC filer profile

How TiGenix is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARTiGenix NV2
  • CIK0001581987
  • Filer statusNon-accelerated filer2
  • Incorporated inBelgium2
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • Business addressRomeinse Straat 12 Box 2, 3001, Leuven, C9 00000002
  • Phone349180609462
  • Shares outstanding259,956,369 as of Dec 31, 20176
  • On EDGAR sinceJul 24, 20132
  • Filings181 in all: 6-K (80), SC 14D9/A (12), UPLOAD (11), SC TO-T/A (9), F-1/A (8), SC TO-C (8), SC14D9C (8), CORRESP (7)2
    All 32 form types

    DRS/A (4), DRSLTR (4), SC 13G (3), 20-F (2), 6-K/A (2), CT ORDER (2), D (2), EFFECT (2), SC 13D (2), 15-12B (1), 20-F/A (1), 25 (1), 424B4 (1), 8-A12B (1), CERTNAS (1), DRS (1), F-1 (1), F-6 (1), F-6/A (1), FWP (1), SC 13D/A (1), SC 13G/A (1), SC 14D9 (1), SC TO-T (1)

  • Latest filingsAnnual report (20-F) Apr 16, 2018

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6